Liminatus Pharma LLCLIMN
13F holders, Q2 2026 (June 30)14holders −1
4new positions
5sold out
1famous investor
$0.11avg. 13F price*
At the end of Q2 2026, 14 institutions reported holding Liminatus Pharma LLC (LIMN) in their 13F filings, down 1 from Q1 2026. 4 opened new positions and 5 sold out. The largest holders were Cygnus Capital Advisors, LLC ($36K), XTX Topco Ltd ($24K) and Geode Capital Management, LLC ($15K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Liminatus Pharma LLC
- CUSIP
- 53271X108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $33K |
| Exits | 5 | $22K |
All 13F filers, Q1 2026 → Q2 2026: 313,042 shares bought and 842,525 shares sold, net −529,483 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Cygnus Capital Advisors, LLC | 0.02% | Reduce -5.9% | 329,333 | $36K |
| XTX Topco Ltd | 0.00% | New | 221,839 | $24K |
| Geode Capital Management, LLC | 0.00% | Add +17.5% | 138,418 | $15K |
| Citadel Advisors | 0.00% | Reduce -91.7% | 56,089 | $6K |
| Vanguard Capital Management LLC | 0.00% | No change | 50,440 | $6K |
| Goldman Sachs Group Inc. | 0.00% | New | 40,220 | $4K |
| StoneX Group Inc. | 0.00% | New | 26,058 | $4K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 22,984 | $3K |
| State Street Corp. | 0.00% | No change | 19,000 | $2K |
| UBS Group AG | 0.00% | Reduce -69.3% | 16,730 | $2K |
| Vanguard Personalized Indexing Management, LLC | 0.00% | Reduce -62.1% | 13,148 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -6.3% | 7,093 | $783 |
| Barclays PLC | 0.00% | New | 4,290 | $474 |
| BlackRock, Inc. | 0.00% | Reduce -97.6% | 313 | $35 |
"% of holder's portfolio" is LIMN's weight in each manager's 13F, not the share of Liminatus Pharma LLC the manager owns.